These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 39276594)

  • 1. Dissecting AI-based mutation prediction in lung adenocarcinoma: A comprehensive real-world study.
    Dernbach G; Kazdal D; Ruff L; Alber M; Romanovsky E; Schallenberg S; Christopoulos P; Weis CA; Muley T; Schneider MA; Schirmacher P; Thomas M; Müller KR; Budczies J; Stenzinger A; Klauschen F
    Eur J Cancer; 2024 Nov; 211():114292. PubMed ID: 39276594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival.
    Li T; Liu J; Zhou Y; Huang S; Wang D; Chen J; Fu Y; He P
    Cancer Med; 2024 May; 13(10):e7227. PubMed ID: 38770632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using Vision Transformer for high robustness and generalization in predicting EGFR mutation status in lung adenocarcinoma.
    Weng L; Xu Y; Chen Y; Chen C; Qian Q; Pan J; Su H
    Clin Transl Oncol; 2024 Jun; 26(6):1438-1445. PubMed ID: 38194018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computed Tomography-Based Radiomics Signature: A Potential Indicator of Epidermal Growth Factor Receptor Mutation in Pulmonary Adenocarcinoma Appearing as a Subsolid Nodule.
    Yang X; Dong X; Wang J; Li W; Gu Z; Gao D; Zhong N; Guan Y
    Oncologist; 2019 Nov; 24(11):e1156-e1164. PubMed ID: 30936378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non-small cell lung cancer patients.
    Ding Y; Zhang L; Guo L; Wu C; Zhou J; Zhou Y; Ma J; Li X; Ji P; Wang M; Zhu W; Shi C; Li S; Wu W; Zhu W; Xiao D; Fu C; He Q; Sun R; Mao X; Lizaso A; Li B; Han-Zhang H; Zhang Z
    Thorac Cancer; 2020 Jan; 11(1):103-112. PubMed ID: 31692283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Prevalence of EGFR Mutations in Lung Adenocarcinomas From Brazilian Patients Harboring the TP53 p.R337H Variant.
    Barbosa MVR; Cordeiro de Lima VC; Formiga MN; Andrade de Paula CA; Torrezan GT; Carraro DM
    Clin Lung Cancer; 2020 Mar; 21(2):e37-e44. PubMed ID: 31889631
    [No Abstract]   [Full Text] [Related]  

  • 7. Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT-based radiomics signature.
    Wang X; Kong C; Xu W; Yang S; Shi D; Zhang J; Du M; Wang S; Bai Y; Zhang T; Chen Z; Ma Z; Wang J; Dong G; Sun M; Yin R; Chen F
    Thorac Cancer; 2019 Oct; 10(10):1904-1912. PubMed ID: 31414580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep learning-based analysis of EGFR mutation prevalence in lung adenocarcinoma H&E whole slide images.
    Park JH; Lim JH; Kim S; Kim CH; Choi JS; Lim JH; Kim L; Chang JW; Park D; Lee MW; Kim S; Park IS; Han SH; Shin E; Roh J; Heo J
    J Pathol Clin Res; 2024 Nov; 10(6):e70004. PubMed ID: 39358807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of combining clinical factors,
    Lue KH; Chen YH; Chu SC; Lin CB; Wang TF; Liu SH
    Ann Nucl Med; 2024 Aug; 38(8):647-658. PubMed ID: 38704786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung: Study in a tertiary care hospital.
    Ghosh M; Mukhopadhyay M; Das C; Chatterjee S; Naskar BG
    J Cancer Res Ther; 2021; 17(6):1389-1396. PubMed ID: 34916369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel radiomic nomogram for predicting epidermal growth factor receptor mutation in peripheral lung adenocarcinoma.
    Lu X; Li M; Zhang H; Hua S; Meng F; Yang H; Li X; Cao D
    Phys Med Biol; 2020 Mar; 65(5):055012. PubMed ID: 31978901
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Biton J; Mansuet-Lupo A; Pécuchet N; Alifano M; Ouakrim H; Arrondeau J; Boudou-Rouquette P; Goldwasser F; Leroy K; Goc J; Wislez M; Germain C; Laurent-Puig P; Dieu-Nosjean MC; Cremer I; Herbst R; Blons H; Damotte D
    Clin Cancer Res; 2018 Nov; 24(22):5710-5723. PubMed ID: 29764856
    [No Abstract]   [Full Text] [Related]  

  • 13. Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with non-squamous non-small cell lung cancer in New Zealand.
    Aye PS; Tin Tin S; McKeage MJ; Khwaounjoo P; Cavadino A; Elwood JM
    BMC Cancer; 2020 Jul; 20(1):658. PubMed ID: 32664868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.
    Wang F; Zhao N; Gao G; Deng HB; Wang ZH; Deng LL; Yang Y; Lu C
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):2851-2859. PubMed ID: 32743759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations.
    Ruiz-Cordero R; Ma J; Khanna A; Lyons G; Rinsurongkawong W; Bassett R; Guo M; Routbort MJ; Zhang J; Skoulidis F; Heymach J; Roarty EB; Tang Z; Medeiros LJ; Patel KP; Luthra R; Roy-Chowdhuri S
    BMC Cancer; 2020 Jan; 20(1):83. PubMed ID: 32005111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymph node metastasis in early invasive lung adenocarcinoma: Prediction model establishment and validation based on genomic profiling and clinicopathologic characteristics.
    Guo W; Lu T; Song Y; Li A; Feng X; Han D; Cao Y; Sun D; Gong X; Li C; Jin R; Du H; Chen K; Xiang J; Hang J; Chen G; Li H
    Cancer Med; 2024 Jul; 13(14):e70039. PubMed ID: 39046176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting EGFR mutation status in lung adenocarcinoma on computed tomography image using deep learning.
    Wang S; Shi J; Ye Z; Dong D; Yu D; Zhou M; Liu Y; Gevaert O; Wang K; Zhu Y; Zhou H; Liu Z; Tian J
    Eur Respir J; 2019 Mar; 53(3):. PubMed ID: 30635290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
    Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
    J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu C; Rao X; Lin W
    Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of multi-center
    Zuo Y; Liu L; Chang C; Yan H; Wang L; Sun D; Ruan M; Lei B; Xia X; Xie W; Song S; Huang G
    Med Phys; 2024 Jul; 51(7):4872-4887. PubMed ID: 38285641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.